74th HUPO World 2026

Sep 27 - Oct 1, 2026  | Singapore

AFFINISEP BREAKFAST SEMINAR

Expanding the Immunopeptidome with Alternative Fragmentation Strategies

Tuesday, September 29, 2026 | 7:45 - 8:45 AM

HUPO World 2026 Breakfast Seminar

Tuesday, September 29, 2026 | 7:45 - 8:45 AM

Expanding the Immunopeptidome with Alternative Fragmentation Strategies


This seminar will present innovative Affinisep SPE kits designed to streamline sample preparation in MS-based proteomics. After a quick overview of Affinisep's know-how for sample preparation in MS-based proteomics by Dr. Kaynoush Naraghi, we will have the pleasure of welcoming A/Prof Dr. Pouya Faridi, Head of the Translational Antigen Discovery Laboratory at Hudson Institute of Medical Research, and Director of the Clinical Proteomics Facility in the Department of Medicine, School of Clinical Sciences at Monash Health Hudson Institute of Medical Research.


He will present that mass spectrometry-based immunopeptidomics remains largely shaped by conventional HCD fragmentation, which may bias peptide identification toward spectra that are best suited to existing search and prediction workflows. 

They have optimised several alternative fragmentation strategies for HLA peptide analysis and found that complementary approaches, including IRMPD and EThcD, can expand the detectable immunopeptidome repertoire beyond standard HCD workflows.
Importantly, this expansion is not uniform and appears to depend on peptide features and HLA allele context. These findings highlight fragmentation strategies as an important experimental variable in immunopeptidomics and suggest that alternative fragmentation can reveal additional HLA-presented peptides while providing richer fragment-ion information for antigen discovery and validation.

Register for Affinisep Breakfast Seminar

Register and secure your seat now!

Please note that you will automatically be enrolled in our monthly newsletter by registering.
Unsubscribe at any time.

AFFINISEP AT  HUPO WORLD 2026

Affinisep develops and manufactures from A to Z high quality and ready-to-use microelution SPE kits to simplify sample preparation in proteomics, and help you achieve highly reliable results. Available with a wide range of formats and capacities Affinisep’s kits are the ideal solutions for various applications and workflows, from few samples processed manually, to high throughput processing of hundreds of samples, and this applies to samples ranging from single-cell analysis to peptide quantities up to several mg.

00
DAYS
:
00
HOURS
:
00
MINUTES
:
00
SECONDS
left to register!

SPEAKER INFORMATION


Dr. Kaynoush Naraghi

Dr. Kaynoush Naraghi is the CEO and co-founder of Affinisep, a life sciences company specializing in innovative sample preparation technologies. Holding a PhD in Polymer Chemistry, Kaynoush began her career in research and development before transitioning into executive leadership in 2004.

Kaynoush leads strategic R&D investments and oversees the development of advanced sample-preparation kits for proteomics, food quality control, and water analysis. These solutions are designed to enhance accuracy, efficiency, and reproducibility in complex analytical workflows, helping scientists and laboratories achieve more reliable results across a wide range of testing environments.


A/Prof Dr. Pouya Faridi

Associate Professor Pouya Faridi leads the Translational Antigen Discovery Laboratory at Monash University and the Hudson Institute of Medical Research and directs the Monash Clinical Proteomics Node. He is co-chair of the HUPO Human Immuno-Peptidome Project, a global initiative focused on advancing technologies, standards, and applications in immunopeptidomics.
His work focuses on developing and translating advanced mass spectrometry-based technologies for immunopeptidomics and clinical proteomics, with the aim of improving antigen discovery for cancer immunotherapy, vaccine development and immune monitoring. His team develops high-throughput and sensitive workflows to identify HLA-presented peptides from cell lines, patient tissues, and body fluids, bridging technology development with translational immunology to enable clinically relevant antigen discovery and validation.

Please find out more about our proteomics products